The Institute for Clinical and Economic Review (ICER) delivered its draft evidence report assessing the cost effectiveness of anti-amyloid antibodies that may win accelerated approval from the US Food and Drug Administration in early 2023, saying on 22 December that Eisai Co., Ltd./Biogen, Inc.’s lecanemab and Eli Lilly and Company’s donanemab would be cost-effective at pricing of $8,500-$20,600 per year. Even at the high end, however, that’s almost $10,000 below lecanemab’s anticipated list price.
Analysts have said they expect Eisai, the lead partner in development and commercialization of lecanemab, to launch the amyloid protofibril-clearing antibody for early Alzheimer’s disease at or slightly below the last list price for Aduhelm (aducanumab), which was $28,200. (Also see "Biogen Halves Aduhelm Price, Readies $500m In Cost Cuts" - Scrip, 20 December, 2021
Important ICER Dates
Dates to remember as ICER continues its assessment of lecanemab and donanemab pricing:
-
5 January 2023: Webinar in which ICER chief medical officer David Rind will present initial findings of the draft report
-
2 February 2023: Public comments on the draft report due by 5 p.m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
